Carregant...

Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib

The overall survival for patients with advanced hepatocellular carcinoma (HCC) is still limited. Although the multi-kinase inhibitor sorafenib has recently been approved for this disease, response rates are still low and patients often face dose-limiting toxicities which lead to a reduction in progn...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wich, Christina, Agaimy, Abbas, Strobel, Deike, Wissniowski, Thaddäus Till, Hartmann, Arndt, Ocker, Matthias
Format: Artigo
Idioma:Inglês
Publicat: The WJG Press and Baishideng 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2909561/
https://ncbi.nlm.nih.gov/pubmed/20653070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v16.i28.3592
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!